XML 56 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Redeemable Convertible Preferred Stock and Equity (Deficit) - USD ($)
$ in Thousands
Total
Astra Zeneca [Member]
FibroGen Europe [Member]
Senior Preferred Stock [Member]
Senior Preferred Stock [Member]
Astra Zeneca [Member]
Senior Preferred Stock [Member]
FibroGen Europe [Member]
Junior Preferred Stock [Member]
Junior Preferred Stock [Member]
Astra Zeneca [Member]
Junior Preferred Stock [Member]
FibroGen Europe [Member]
Common Stock [Member]
Common Stock [Member]
Astra Zeneca [Member]
Common Stock [Member]
FibroGen Europe [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Astra Zeneca [Member]
Additional Paid-in Capital [Member]
FibroGen Europe [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Loss [Member]
Astra Zeneca [Member]
Accumulated Other Comprehensive Loss [Member]
FibroGen Europe [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Astra Zeneca [Member]
Accumulated Deficit [Member]
FibroGen Europe [Member]
Noncontrolling Interest [Member]
Noncontrolling Interest [Member]
Astra Zeneca [Member]
Noncontrolling Interest [Member]
FibroGen Europe [Member]
Balance at Dec. 31, 2013 $ (60,833)     $ 168,436     $ 136,313     $ 132     $ 41,134     $ (3,508)     $ (262,779)     $ 27,875    
Balance, Shares at Dec. 31, 2013       38,340,182     46,460,057     13,201,264                            
Net loss (59,504)     $ 0     $ 0     $ 0     0     0     (59,504)     0    
Change in unrealized loss on investments (1,723)     0     0     0     0     (1,723)     0     0    
Foreign currency translation adjustments 2,082     0     0     0     0     2,082     0     0    
Stock options exercised 1,694     $ 0     $ 0     $ 5     1,689     0     0     0    
Stock options exercised, Shares       0     0     539,971                            
Stock-based compensation 18,698     $ 0     $ 0     $ 0     18,698     0     0     0    
Conversion of preferred stock to common stock 168,436   $ 0     $ 0     $ 0 $ 339   $ 10 304,410   $ 8,594 0   $ 0 0   $ 0 0    
Conversion of preferred stock to common stock       $ (168,436)     $ (136,313)                                 $ (8,604)
Conversion of preferred stock to common stock, shares           0     0 33,919,954   958,996                        
Conversion of preferred stock to common stock, shares       (38,340,182)     (46,460,057)                                  
Initial Public Offering, net of underwriting discounts, commission and issuance costs 151,826     $ 0     $ 0     $ 93     151,733     0     0     0    
Initial Public Offering, net of underwriting discounts, commission and issuance costs, shares       0     0     9,315,000                            
Astra Zeneca private placement   $ 20,000     $ 0     $ 0     $ 11     $ 19,989     $ 0     $ 0     $ 0  
Astra Zeneca private placement, Shares         0     0     1,111,111                          
Balance at Dec. 31, 2014 240,676     $ 0     $ 0     $ 590     546,247     (3,149)     (322,283)     19,271    
Balance, Shares at Dec. 31, 2014       0     0     59,046,296                            
Net loss (85,779)     $ 0     $ 0     $ 0     0     0     (85,779)     0    
Change in unrealized loss on investments (164)     0     0     0     0     (164)     0     0    
Foreign currency translation adjustments 1,662     0     0     0     0     1,662     0     0    
Stock options exercised 10,112     $ 0     $ 0     $ 24     10,088     0     0     0    
Stock options exercised, Shares       0     0     2,361,633                            
Shares issued upon vesting of restricted stock units, net of payroll taxes paid, and purchases made under the employee stock purchase plan 2,595     $ 0     $ 0     $ 5     2,590     0     0     0    
Shares issued upon vesting of restricted stock units, net of payroll taxes paid, and purchases made under the employee stock purchase plan, shares       0     0     456,355                            
True up of issuance costs related to initial public offering and common stock sold by FibroGen Europe 42     $ 0     $ 0     $ 0     42     0     0     0    
Stock-based compensation 27,681     0     0     0     27,681     0     0     0    
Warrants exercised 0     $ 0     $ 0     $ 1     (1)     0     0     0    
Warrants exercised, Shares       0     0     120,795                            
Balance at Dec. 31, 2015 196,825     $ 0     $ 0     $ 620     586,647     (1,651)     (408,062)     19,271    
Balance, Shares at Dec. 31, 2015       0     0     61,985,079                            
Net loss (61,680)     $ 0     $ 0     $ 0     0     0     (61,680)     0    
Change in unrealized loss on investments 159     0     0     0     0     159     0     0    
Foreign currency translation adjustments 532     0     0     0     0     532     0     0    
Stock options exercised 5,907     $ 0     $ 0     $ 12     5,895     0     0     0    
Stock options exercised, Shares       0     0     1,169,103                            
Shares issued upon vesting of restricted stock units, net of payroll taxes paid, and purchases made under the employee stock purchase plan 1,234     $ 0     $ 0     $ 5     1,229     0     0     0    
Shares issued upon vesting of restricted stock units, net of payroll taxes paid, and purchases made under the employee stock purchase plan, shares       0     0     491,656                            
Stock appreciation rights settled 0     $ 0     $ 0     $ 0     0     0     0     0    
Stock appreciation rights settled, Shares       0     0     17,855                            
Stock-based compensation 32,132     $ 0     $ 0     $ 0     32,132     0     0     0    
Warrants exercised 0     $ 0     $ 0     $ 0     0     0     0     0    
Warrants exercised, Shares       0     0     1,591                            
Balance at Dec. 31, 2016 $ 175,109     $ 0     $ 0     $ 637     $ 625,903     $ (960)     $ (469,742)     $ 19,271    
Balance, Shares at Dec. 31, 2016       0     0     63,665,284